<DOC>
	<DOCNO>NCT02735915</DOCNO>
	<brief_summary>The purpose study evaluate persistence immune response HZ vaccine well safety 10 year first dose initial vaccination course . This study also assess immune response re-vaccination 2 additional dos HZ/su administer ten year first dose initial vaccination course study Zoster-003 ( NCT00434577 ) .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety GSK Biologicals ' Herpes Zoster Subunit ( HZ/su ) Vaccine 9 10 Years After Vaccine Administration Assessment Re-vaccination With 2 Additional Doses 10 Years After Initial Vaccination , Healthy Subjects Aged 60 Years Age ( YOA ) Older</brief_title>
	<detailed_description>In LTFU study ( ZOSTER-060 ) , subject receive 2 dos HZ/su earlier Zoster-003 ( NCT00434577 ) study follow Month 108/Year 9 Month 120/Year 10 post first dose vaccine safety immunogenicity ( humoral cellular ) . In order assess effect re-vaccination 2 additional dos HZ/su vaccine , subject receive 2 additional dos HZ/su vaccine , 0 , 2-month schedule ten year initial vaccination course study Zoster-003 ( NCT00434577 ) , follow reactogenicity , safety humoral cellular immunogenicity ( include persistence ) . In alignment previous persistence timepoints , study control group .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol ( e.g. , completion diary card , return followup visit , ability schedule contact allow evaluation study ) . Or subject caregiver , opinion investigator , comply requirement protocol ( e.g. , completion diary card , vaccination visit , availability followup contact ) . Written inform consent obtain subject prior performance study specific procedure . Previous participation study ZOSTER003 ( NCT00434577 ) , group 50 µg gE / AS01B , complete vaccination course ( 2 dos HZ/su ) study ZOSTER003 ( NCT00434577 ) . Subjects expect enter study ( complete Visit 1 ) time turn 108 month first vaccination previous vaccination course HZ/su later 111 month . Use investigational nonregistered product ( drug vaccine ) study vaccine period start 30 day first study visit ( Day 29 Day 0 ) , plan use study period . Use anticipated use immunosuppressant immunemodifying drug period start six month prior study start whole study period . This include chronic administration corticosteroid ( &gt; 14 consecutive day prednisone dose ≥20 mg/day [ equivalent ] ) , longacting immunemodifying agent ( e.g. , infliximab ) immunosuppressive/cytotoxic therapy ( e.g. , medication use cancer chemotherapy , organ transplantation treat autoimmune disorder ) . Any confirm suspect immunosuppressive immunodeficient condition result disease ( e.g. , malignancy , human immunodeficiency virus [ HIV ] infection ) . Administration plan administration live vaccine period start 30 day first dose study vaccine end 30 day last dose study vaccine , , administration plan administration nonreplicating vaccine* within 8 day prior within 14 day either dose study vaccine . E.g. , inactivate subunit vaccine , include inactivated subunit influenza vaccine pneumococcal conjugate vaccine . Previous vaccination HZ since initial vaccination Zoster003 . Administration immunoglobulins and/or blood product period start 3 month study start , plan administration study period . History previous HZ .</criteria>
	<gender>All</gender>
	<minimum_age>68 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Long term follow-up</keyword>
	<keyword>Adults</keyword>
	<keyword>Herpes zoster</keyword>
</DOC>